Archives for Biologics

Accidental Fear or Valid reporting? Risk of New IBD Rises for Patients Treated With Etanercept

The Center for Biosimilars today published an article that concluded that there is a fearful risk of being diagnosed with IBD Crohn’s or Colitis for those currently being treated with Etanercept. Respectfully, I believe this study is incomplete and does not tell the full story. Though I don’t currently have access to the full study, just the Wiley Online Library Summary and the Center for Biosimilars article, until Lifestyle and Diet are factored into these studies I believe they do not tell the complete story.  20 years of clinical and cost outcomes from Integrative Medicine* have demonstrated the following results:
Read More

Categories: Abdominal Pain, alopecia, ankylosing spondylitis, Biologics, C-reactive protein (CRP), CalProctetin, Crohn's Disease, DIAGNOSTIC TESTING, Joel's Story, pemphigus, Pharmaceuticals, psoriasis, Recommended Resources, RESEARCH, Resources, Rheumatoid Arthritis, Stool Analysis, SYMPTOMS, TREATMENT, Ulcerative Colitis, and vitiligo.

US FDA approves Stelara for ulcerative colitis

This website is at great risk of being removed. Please donate today so we may continue this service so humanity may prosper in a peaceful world with a peaceful microbiome This past October, the U.S. Food and Drug Administration approved ustekinumab (Stelara by Janssen), a human IL-12 and IL-23 antagonist. This is based on data from a phase 3 UNIFI trial, which demonstrated that ustekinumab induced and maintained clinical remission in a significantly greater proportion of adults with moderately to severely active UC compared with placebo. Trial And Study Results Janssen said at the time the UNIFI data was released
Read More

Categories: Biologics, C-reactive protein (CRP), CalProctetin, Colonoscopy, Crohn's Disease, Nutrition, One Great Gut Collection, Pharmaceuticals, RESEARCH, Resources, STORIES-OF-HOPE, The Crohn's And Colitis Summit, TREATMENT, and Ulcerative Colitis.

Researchers discover critical link to controlling inflammation in Crohn’s disease

To aggregate the most appropriate IBD news we are republishing this article. This was first reported by Case Western Reserve University in MedicalXpress. We updated the article for further accuracy. (Thank You Dr. Peter Spiegel for bringing this breakthrough to our attention) Investigators at the Case Western Reserve University School of Medicine discovered that blocking interleukin-1α (IL1α), a protein that controls inflammation in the gut, markedly decreases the severity of intestinal inflammation in a mouse model of Crohn’s disease (CD). The anti-inflammatory effects of the biological therapies used to neutralize IL1α were similar to those of steroids, which represent what
Read More

Categories: Biologics, Crohn's Disease, DIAGNOSTIC TESTING, Pharmaceuticals, RESEARCH, and TREATMENT.